计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| A340149-25mg |
25mg |
现货 ![]() |
| |
| A340149-50mg |
50mg |
现货 ![]() |
| |
| A340149-100mg |
100mg |
现货 ![]() |
| |
| A340149-250mg |
250mg |
现货 ![]() |
| |
| A340149-1g |
1g |
现货 ![]() |
|
| 别名 | 阿匹莫德 |
|---|---|
| 英文别名 | GFW2K84S4L | Apilimod [INN] | HY-14644 | AKOS015909602 | N-[6-Morpholin-4-yl-2-(2-pyridin-2-yl-ethoxy)-pyrimidin-4-yl]-N'-[1-m-tolyl-meth-(E)-ylidene]-hydrazine | BA177430 | Apilimod | N-[(E)-(3-methylphenyl)methylideneamino]-6-morpholin-4-yl-2-(2-pyridin |
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | Apilimod |
| 生化机理 | Apilimod(STA-5326)是一种强效的口服活性细胞因子 IL-12 和 IL-23 选择性抑制剂。Apilimod 通过抑制 TLR-4 调节脂质激酶 PIKfyve(磷脂酰肌醇-3-磷酸 5-激酶)的磷酸转移酶活性,选择性地抑制 IL-12 和 IL-23 的合成。它能抑制 Th1 细胞在体内的反应,减少炎性组织病理变化。此外,它还在两种细胞系中表现出很强的抗 COVID-19 活性(Vero E6:IC50 < 0.08 μM;A549-ACE2:IC50 = 0.007 μM)。阿匹莫德能有效减少 SARS-CoV S 假病毒进入 293/hACE2 细胞。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 1-磷脂酰肌醇 3-磷酸 5-激酶抑制剂 |
| 产品介绍 |
Apilimod是细胞因子IL-12和IL-23产生的有效抑制剂。IL-12和IL-23是某些自身免疫和炎性疾病的潜在调节剂。|也可以使用以下水溶性盐形式:|盐酸阿比利莫德|甲磺酸阿比利莫德 Apilimod is a potent inhibitor of the cytokines IL-12 and IL-23 production. IL-12 and IL-23 are potential regulators of certain autoimmune and inflammatory diseases.|The following water-soluble salt forms are also available:|Apilimod Hydrochloride |Apilimod mesylate |
| 纯度 | ≥98% |
| ALogP | 3.8 |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 504765295 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | N-[(E)-(3-methylphenyl)methylideneamino]-6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-amine |
| INCHI | 1S/C23H26N6O2/c1-18-5-4-6-19(15-18)17-25-28-21-16-22(29-10-13-30-14-11-29)27-23(26-21)31-12-8-20-7-2-3-9-24-20/h2-7,9,15-17H,8,10-14H2,1H3,(H,26,27,28)/b25-17+ |
| InChi Key | HSKAZIJJKRAJAV-KOEQRZSOSA-N |
| Smiles | CC1=CC(=CC=C1)C=NNC2=CC(=NC(=N2)OCCC3=CC=CC=N3)N4CCOCC4 |
| Isomeric SMILES | CC1=CC(=CC=C1)/C=N/NC2=CC(=NC(=N2)OCCC3=CC=CC=N3)N4CCOCC4 |
| 分子量 | 418.49 |
| Reaxy-Rn | 18539732 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=18539732&ln= |
| 溶解性 | insoluble in H2O; ≥17.9 mg/mL in DMSO; ≥6.86 mg/mL in EtOH with ultrasonic |
|---|---|
| 熔点 | 70-80° C |
| 分子量 | 418.500 g/mol |
| XLogP3 | 3.800 |
| 氢键供体数Hydrogen Bond Donor Count | 1 |
| 氢键受体数Hydrogen Bond Acceptor Count | 8 |
| 可旋转键计数Rotatable Bond Count | 8 |
| 精确质量Exact Mass | 418.212 Da |
| 单同位素质量Monoisotopic Mass | 418.212 Da |
| 拓扑极表面积Topological Polar Surface Area | 84.800 Ų |
| 重原子数Heavy Atom Count | 31 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 544.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 1 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 1 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 象形图 | GHS07 |
|---|---|
| 信号词 | 警告 |
| 危险声明 |
H302: 吞食有害 |
| 预防措施声明 |
P264: 处理后要彻底洗手。 P270: 使用本产品时,请勿进食、饮水或吸烟。 P330: 漱口 P301+P312: 如误吞咽:如感觉不适,呼叫急救中心/医生。 P501: 将内容物/容器处理到。。。 |
| 1. Wada Y, Lu R, Zhou D, Chu J, Przewloka T, Zhang S, Li L, Wu Y, Qin J, Balasubramanyam V et al.. (2007) Selective abrogation of Th1 response by STA-5326, a potent IL-12/IL-23 inhibitor.. Blood, 109 (3): (1156-64). [PMID:17053051] |
| 2. Wada Y, Cardinale I, Khatcherian A, Chu J, Kantor AB, Gottlieb AB, Tatsuta N, Jacobson E, Barsoum J, Krueger JG. (2012) Apilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasis.. PLoS ONE, 7 (4): (e35069). [PMID:22493730] |
| 3. Cai X, Xu Y, Cheung AK, Tomlinson RC, Alcázar-Román A, Murphy L, Billich A, Zhang B, Feng Y, Klumpp M et al.. (2013) PIKfyve, a class III PI kinase, is the target of the small molecular IL-12/IL-23 inhibitor apilimod and a player in Toll-like receptor signaling.. Chem Biol, 20 (7): (912-21). [PMID:23890009] |
| 4. Gayle S, Landrette S, Beeharry N, Conrad C, Hernandez M, Beckett P, Ferguson SM, Mandelkern T, Zheng M, Xu T et al.. (2017) Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma.. Blood, 129 (13): (1768-1778). [PMID:28104689] |
| 5. Nelson EA, Dyall J, Hoenen T, Barnes AB, Zhou H, Liang JY, Michelotti J, Dewey WH, DeWald LE, Bennett RS et al.. (2017) The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection.. PLoS Negl Trop Dis, 11 (4): (e0005540). [PMID:28403145] |
| 6. Baranov MV, Bianchi F, van den Bogaart G. (2020) The PIKfyve Inhibitor Apilimod: A Double-Edged Sword against COVID-19.. Cells, 10 (1): (30). [PMID:33375410] |
| 7. Qiu S, Leung A, Bo Y, Kozak RA, Anand SP, Warkentin C, Salambanga FDR, Cui J, Kobinger G, Kobasa D et al.. (2018) Ebola virus requires phosphatidylinositol (3,5) bisphosphate production for efficient viral entry.. Virology, 513 (17-28). [PMID:29031163] |
| 8. Logue J, Chakraborty AR, Johnson R, Goyal G, Rodas M, Taylor LJ, Baracco L, McGrath ME, Haupt R, Furlong BA et al.. (2022) PIKfyve-specific inhibitors restrict replication of multiple coronaviruses in vitro but not in a murine model of COVID-19.. Commun Biol, 5 (1): (808). [PMID:35962188] |
| 9. Baranov MV, Bianchi F, Schirmacher A, van Aart MAC, Maassen S, Muntjewerff EM, Dingjan I, Ter Beest M, Verdoes M, Keyser SGL et al.. (2019) The Phosphoinositide Kinase PIKfyve Promotes Cathepsin-S-Mediated Major Histocompatibility Complex Class II Antigen Presentation.. iScience, 11 (160-177). [PMID:30612035] |
| 10. Ianevski A, Yao R, Fenstad MH, Biza S, Zusinaite E, Reisberg T, Lysvand H, Løseth K, Landsem VM, Malmring JF et al.. (2020) Potential Antiviral Options against SARS-CoV-2 Infection.. Viruses, 12 (6): [PMID:32545799] |